Transforming growth factor-β gene silencing using adenovirus expressing TGF-β1 or TGF-β2 shRNA

Cancer Gene Therapy

Volumn 20, Issue 2, 2013, Pages 94-100

  Oh, S ^a   Kim, E ^a   Kang, D ^a,b   Kim, M ^a   Kim, J H ^a   Song, J J ^a  

^a Yonsei University College of Medicine   (South Korea)

^b YANBIAN UNIVERSITY   (China)

Author keywords

adenovirus; antitumor; immunosuppression; shRNA; TGF b isotype

Indexed keywords

ADENOVIRUS VECTOR; MESSENGER RNA; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ADENOVIRUS 5; ADENOVIRUS INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SPECIFICITY; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SHUTTLE VECTOR; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENETIC THERAPY; HELA CELLS; HUMANS; IMMUNOSUPPRESSION; NEOPLASMS; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ADENOVIRIDAE;

EID: 84874111849     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.90     Document Type: Article

References (31)

1. Massague J. The TGF-beta family of growth and differentiation factors. Cell 1987; 49: 437-438.
2. Moore LD, Isayeva T, Siegal GP, Ponnazhagan S. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo. Clinical Cancer Res 2008; 14: 4961-4970.
3. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003; 116(Part 2): 217-224.
4. Massague J. TGFbeta in Cancer. Cell 2008; 134: 215-230.
5. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007; 1775: 21-62.
6. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
7. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol 2005; 23: 2078-2093.
8. Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G et al. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res 2008; 68: 10247-10256.
9. Ivanovic V, Demajo M, Krtolica K, Krajnovic M, Konstantinovic M, Baltic V et al. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients. Clin Chim Acta 2006; 371: 191-193.
10. Conroy H, Galvin KC, Higgins SC, Mills KH. Gene silencing of TGF-beta1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells. Cancer Immunol Immunother 2012; 61: 425-431.
11. Wei H, Liu P, Swisher E, Yip YY, Tse JH, Agnew K et al. Silencing of the TGF-beta1 gene increases the immunogenicity of cells from human ovarian carcinoma. J Immunother 2012; 35: 267-275.
12. Ding Y, Kim JK, Kim SI, Na HJ, Jun SY, Lee SJ et al. TGF-{beta}1 protects against mesangial cell apoptosis via induction of autophagy. J Biol Chem 2010; 285: 37909-37919.
13. Dogar AM, Towbin H, Hall J. Suppression of latent transforming growth factor (TGF)-beta1 restores growth inhibitory TGF-beta signaling through microRNAs. J Biol Chem 2011; 286: 16447-16458.
14. Schafer H, Struck B, Feldmann EM, Bergmann F, Grage-Griebenow E, Geismann C et al. TGF-beta1-dependent L1CAM expression has an essential role in macrophage-induced apoptosis resistance and cell migration of human intestinal epithelial cells. Oncogene 2013.
15. Almeida R, Allshire RC. RNA silencing and genome regulation. Trends Cell Biol 2005; 15: 251-258.
16. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007; 59: 75-86.
17. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nature reviews. Drug Discov 2009; 8: 129-138.
18. Zhang H, Kolb FA, Jaskiewicz L, Westhof E, Filipowicz W. Single processing center models for human dicer and bacterial RNase III. Cell 2004; 118: 57-68.
19. Rand TA, Ginalski K, Grishin NV, Wang X. Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc Natl Acad Sci USA 2004; 101: 14385-14389.
20. Kumar LD, Clarke AR. Gene manipulation through the use of small interfering RNA (siRNA): from in vitro to in vivo applications. Adv Drug Deliv Rev 2007; 59: 87-100.
21. Sharma A, Tandon M, Bangari DS, Mittal SK. Adenoviral vector-based strategies for cancer therapy. Curr Drug Ther 2009; 4: 117-138.
22. Douglas JT. Adenoviral vectors for gene therapy. Mol Biotechnol 2007; 36: 71-80.
23. Schlingensiepen KH, Jaschinski F, Lang SA, Moser C, Geissler EK, Schlitt HJ et al. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci 2011; 102: 1193-1200.
24. Olivares J, Kumar P, Yu Y, Maples PB, Senzer N, Bedell C et al. Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res 2011; 17: 183-192.
25. De Crescenzo G, Hinck CS, Shu Z, Zuniga J, Yang J, Tang Y et al. Three key residues underlie the differential affinity of the TGFbeta isoforms for the TGFbeta type II receptor. J Mol Biol 2006; 355: 47-62.
26. Laverty HG, Wakefield LM, Occleston NL, O'Kane S, Ferguson MW. TGF-beta3 and cancer: a review. Cytokine Growth Factor Rev 2009; 20: 305-317.
27. Hinck AP, Archer SJ, Qian SW, Roberts AB, Sporn MB, Weatherbee JA et al. Transforming growth factor beta 1: three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor beta 2. Biochemistry 1996; 35: 8517-8534.
28. Bocharov EV, Blommers MJ, Kuhla J, Arvinte T, Burgi R, Arseniev AS. Sequencespecific 1H and 15N assignment and secondary structure of transforming growth factor beta3. J Biomol NMR 2000; 16: 179-180.
29. Akhurst RJ, Lehnert SA, Faissner A, Duffie E. TGF beta in murine morphogenetic processes: the early embryo and cardiogenesis. Development 1990; 108: 645-656.
30. Bierie B, Moses HL. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 2010; 21: 49-59.
31. Li C, Wang J, Wilson PB, Kumar P, Levine E, Hunter RD et al. Role of transforming growth factor beta3 in lymphatic metastasis in breast cancer. Int J Cancer 1998; 79: 455-459.